Waters remain choppy for Vytorin as SEAS publication renews cancer fears
This article was originally published in Scrip
Merck/Schering-Plough Pharmaceuticals' troubled combination hypolipaemic Vytorin (ezetimibe plus simvastatin) is once again in the spotlight following the presentation of the full SEAS data at the European Society of Cardiology meeting in Munich and their simultaneous publication online in the New England Journal of Medicine.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.